<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1806">
  <stage>Registered</stage>
  <submitdate>13/01/2008</submitdate>
  <approvaldate>13/01/2008</approvaldate>
  <nctid>NCT00604994</nctid>
  <trial_identification>
    <studytitle>Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer</studytitle>
    <scientifictitle>Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer</scientifictitle>
    <utrn />
    <trialacronym>LEGS</trialacronym>
    <secondaryid>LEGS</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Female Genital Diseases</healthcondition>
    <healthcondition>Ovarian Cancer</healthcondition>
    <healthcondition>Cervical Cancer</healthcondition>
    <healthcondition>Endometrial Cancer</healthcondition>
    <healthcondition>Vulval Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Womb (Uterine or endometrial cancer)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Cervical (cervix)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Other reproductive health and childbirth disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Malignant - Patients with malignant gynaecological conditions including cancers of the cervix, uterus, ovary, vulva and vagina

Benign - Patients without malignant gynaecological cancers

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time of onset of lymphoedema after gynaecological cancer treatment.</outcome>
      <timepoint>2 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of lymphoedema after gynaecological cancer treatment.</outcome>
      <timepoint>2 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Point prevalence of lymphoedema after gynaecological cancer treatment.</outcome>
      <timepoint>2 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Severity of lymphoedema after gynaecological cancer treatment.</outcome>
      <timepoint>2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Prevalence of key risk factors of post-treatment lymphoedema among patients with gynaecological cancer.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Impact of risk factors on development of lymphoedema.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lymphoedema development in patients treated for gynaecological cancer compared to patients with benign disease.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients scheduled for surgery of benign or malignant gynaecological diseases as
             determined jointly by the surgeon and the patient.

          -  Non-pregnant female patients.

          -  Over 18 years of age at time of surgery.

          -  Patients who understand the conditions of the study and are willing to participate for
             the length of the prescribed term of follow-up.

          -  Patients who are capable of, and have given, informed consent to their participation
             in the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients with a pacemaker.

          -  Allergies against adhesive electrodes and extensive internal metal plates are
             ineligible for BIS measurement.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>761</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>The Wesley Hospital - Auchenflower</hospital>
    <hospital>Greenslopes Private Hospital - Greenslopes</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Herston</hospital>
    <hospital>Mater Health Services - South Brisbane</hospital>
    <hospital>Royal Women's Hospital - Carlton</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>4066 - Auchenflower</postcode>
    <postcode>4120 - Greenslopes</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>3053 - Carlton</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Queensland Centre for Gynaecological Cancer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>The University of Queensland</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Royal Brisbane and Women's Hospital</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Mater Health Services, Brisbane</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Mater Private Hospital</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Queensland Institute of Medical Research</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Queensland University of Technology</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australia New Zealand Gynaecological Oncology Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cancer Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This project will conduct a prospective, longitudinal, observational cohort study to assess
      the onset and incidence of lymphoedema, as well as investigate factors associated with its
      development among women newly diagnosed with gynaecological cancers in 2008 to 2011.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00604994</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andreas Obermair, MD FRANZCOG CGO</name>
      <address>Queensland Centre for Gynaecological Cancer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>